Loading...
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
Abstract De-escalating adjuvant therapy following pathologic complete response (pCR) to an abbreviated neoadjuvant regimen in human epidermal growth factor receptor 2-positive (HER2+) breast cancer is the focus of international research efforts. However, the feasibility of this approach and its appe...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
Nature Portfolio
2022-05-01
|
Serier: | npj Breast Cancer |
Online adgang: | https://doi.org/10.1038/s41523-022-00429-7 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|